144 related articles for article (PubMed ID: 25008234)
1. The survival decrease in gastric cancer is associated with the methylation of B-cell CLL/lymphoma 6 member B promoter.
Deng J; Liang H; Dong Q; Hou Y; Xie X; Yu J; Fan D; Hao X
Open Biol; 2014 Jul; 4(7):. PubMed ID: 25008234
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival.
Xu L; Li X; Chu ES; Zhao G; Go MY; Tao Q; Jin H; Zeng Z; Sung JJ; Yu J
Gut; 2012 Jul; 61(7):977-85. PubMed ID: 21917650
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.
Deng J; Liang H; Ying G; Dong Q; Zhang L; Yu J; Fan D; Hao X
J Am Coll Surg; 2014 Nov; 219(5):904-13. PubMed ID: 25260683
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer.
Hou YC; Deng JY; Zhang RP; Xie XM; Cui JL; Wu WP; Hao XS; Liang H
Cancer Biomark; 2015; 15(5):567-73. PubMed ID: 26406945
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of BCL6B gene is a potential plasma DNA biomarker for gastric cancer.
Yang Q; Gao J; Xu L; Zeng Z; Sung JJ; Yu J
Biomarkers; 2013 Dec; 18(8):721-5. PubMed ID: 24191714
[TBL] [Abstract][Full Text] [Related]
6. Methylation of ASC/TMS1 promoter is associated with poor prognosis of patients with gastric cancer.
Wu L; Zhang C; Wang X; Ding X; Deng J; Liang H
Clin Transl Oncol; 2016 Mar; 18(3):296-303. PubMed ID: 26260914
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of E3 ubiquitin ligase RNF180 DNA promoter to predict the survival of gastric cancer.
Xie XM; Deng JY; Hou YC; Cui JL; Wu WP; Ying GG; Dong QP; Hao XS; Liang H
Cancer Biomark; 2015; 15(3):259-65. PubMed ID: 25769451
[TBL] [Abstract][Full Text] [Related]
8. Applicability of the methylated CpG sites of paired box 5 (PAX5) promoter for prediction the prognosis of gastric cancer.
Deng J; Liang H; Zhang R; Dong Q; Hou Y; Yu J; Fan D; Hao X
Oncotarget; 2014 Sep; 5(17):7420-30. PubMed ID: 25277182
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer.
Kanda M; Shimizu D; Nomoto S; Takami H; Hibino S; Oya H; Hashimoto R; Suenaga M; Inokawa Y; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Gastric Cancer; 2015 Apr; 18(2):288-96. PubMed ID: 24695972
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of FAT4 contributes to gastric field cancerization.
Yoshida S; Yamashita S; Niwa T; Mori A; Ito S; Ichinose M; Ushijima T
Gastric Cancer; 2017 Jan; 20(1):136-145. PubMed ID: 26792292
[TBL] [Abstract][Full Text] [Related]
11. Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
Amini M; Hejazi M; Ghorban K; Mokhtarzadeh A; Baradaran B
Gene; 2021 Mar; 772():145376. PubMed ID: 33359128
[TBL] [Abstract][Full Text] [Related]
12. B cell CLL/lymphoma 6 member B inhibits hepatocellular carcinoma metastases in vitro and in mice.
Wang J; Dong L; Xu L; Chu ES; Chen Y; Shen J; Li X; Wong CC; Sung JJ; Yu J
Cancer Lett; 2014 Dec; 355(2):192-200. PubMed ID: 25218345
[TBL] [Abstract][Full Text] [Related]
13. Methylation-dependent activation of CDX1 through NF-κB: a link from inflammation to intestinal metaplasia in the human stomach.
Rau TT; Rogler A; Frischauf M; Jung A; Konturek PC; Dimmler A; Faller G; Sehnert B; El-Rifai W; Hartmann A; Voll RE; Schneider-Stock R
Am J Pathol; 2012 Aug; 181(2):487-98. PubMed ID: 22749770
[TBL] [Abstract][Full Text] [Related]
14. Mediation of the malignant biological characteristics of gastric cancer cells by the methylated CpG islands in RNF180 DNA promoter.
Deng J; Guo J; Guo X; Hou Y; Xie X; Sun C; Zhang R; Yu X; Liang H
Oncotarget; 2016 Jul; 7(28):43461-43474. PubMed ID: 27223257
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the claudin‑3 promoter predicts the prognosis of advanced gastric adenocarcinoma.
Zhang Z; Yu W; Chen S; Chen Y; Chen L; Zhang S
Oncol Rep; 2018 Jul; 40(1):49-60. PubMed ID: 29749528
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of DNA methylation is associated with tumor stage in gastric cancer.
Oue N; Mitani Y; Motoshita J; Matsumura S; Yoshida K; Kuniyasu H; Nakayama H; Yasui W
Cancer; 2006 Mar; 106(6):1250-9. PubMed ID: 16475210
[TBL] [Abstract][Full Text] [Related]
17. Site-specific Hypermethylation of RUNX3 Predicts Poor Prognosis in Gastric Cancer.
Wang N; Sui F; Ma J; Su X; Liu J; Yao D; Shi B; Hou P; Yang Q
Arch Med Res; 2016 May; 47(4):285-92. PubMed ID: 27664488
[TBL] [Abstract][Full Text] [Related]
18. Profile of methylated CpG sites of hMLH1 promoter in primary gastric carcinoma with microsatellite instability.
Kang GH; Lee S; Shim YH; Kim JC; Ro JY
Pathol Int; 2002 Dec; 52(12):764-8. PubMed ID: 12588445
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of RUNX3 methylation in neoplastic and non-neoplastic gastric epithelia using a DNA microarray.
So K; Tamura G; Honda T; Homma N; Endoh M; Togawa N; Nishizuka S; Motoyama T
Pathol Int; 2006 Oct; 56(10):571-5. PubMed ID: 16984612
[TBL] [Abstract][Full Text] [Related]
20. Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer.
Zhang H; Song Y; Xia P; Cheng Y; Guo Q; Diao D; Wang W; Wu X; Liu D; Dang C
Med Oncol; 2014 Feb; 31(2):830. PubMed ID: 24381142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
